Medication-induced pulmonary toxicity is a rare adverse event that may occur with many chemotherapeutic agents, including etoposide. This agent has been found to cause various toxicities, including anaphylaxis, angioedema, hypotension, and pneumonitis. Etoposide is used in chemotherapy regimens for multiple cancers, including germ-cell tumors. Proper diagnosis of chemotherapy-induced pulmonary toxicity is imperative and should be considered in patients who develop acute respiratory failure during or after chemotherapy. Here, we discuss an unexpected case of etoposide-induced pneumonitis after a short course of IV etoposide in a patient with metastatic seminoma.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11897678 | PMC |
| http://dx.doi.org/10.7759/cureus.78791 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Breathtaking Case of Chemotherapy-Induced Pneumonitis.
Cureus
February 2025
Internal Medicine, Henry Ford Health System - Warren, Warren, USA.
Medication-induced pulmonary toxicity is a rare adverse event that may occur with many chemotherapeutic agents, including etoposide. This agent has been found to cause various toxicities, including anaphylaxis, angioedema, hypotension, and pneumonitis. Etoposide is used in chemotherapy regimens for multiple cancers, including germ-cell tumors.
View Article and Find Full Text PDFNutritional Status and Its Impact on Treatment Tolerance in Non-Small-Cell Lung Cancer Patients Receiving Osimertinib.
Nutrients
March 2025
Pharmacy Department, University Hospital Complex of Vigo, 36312 Vigo, Spain.
: Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases and is a leading cause of morbidity and mortality worldwide. Between 35% and 65% of NSCLC patients experience nutritional problems or malnutrition, which significantly affects their prognosis and quality of life. This study aims to describe the nutritional status and body composition of NSCLC patients treated with osimertinib, an oral tyrosine kinase inhibitor, while also assessing the prevalence of sarcopenia, presarcopenia, and dynapenia.
View Article and Find Full Text PDFPanduratin A from Effectively Inhibits EGFR/STAT3/Akt Signaling Pathways, Inducing Apoptosis in NSCLC Cells with Wild-Type and T790M Mutations in EGFR.
Int J Mol Sci
March 2025
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Srinakharinwirot University, Nakhon Nayok 26120, Thailand.
Non-small cell lung cancer (NSCLC) is a challenging disease, with the epidermal growth factor receptor (EGFR) being a key target for new, effective treatments crucial for the signaling pathways regulating cancer cell survival. Targeting EGFR-mediated signaling offers promising strategies to improve NSCLC therapies, particularly in overcoming resistance in EGFR-mutant lung cancer. In this study, we investigated the anticancer effects of panduratin A, a naturally occurring flavonoid from , on human NSCLC cell lines expressing both wild-type EGFR (A549) and mutant EGFR (H1975) using in vitro experiments and molecular docking approaches.
View Article and Find Full Text PDFEffects of Vinorelbine on M2 Macrophages in Non-Small Cell Lung Cancer.
Int J Mol Sci
March 2025
Department of Basic Oncology, Institute of Health Sciences, Ege University, Bornova 35100, Izmir, Turkey.
Tumor-associated macrophages (TAMs) significantly influence tumor progression and patient responses to conventional chemotherapy. However, the interplay between anti-cancer drugs, immune responses in the tumor microenvironment, and their implications for cancer treatment remains poorly understood. This study investigates the effects of vinorelbine on M2 macrophages in lung cancer and its capacity to modulate TAMs toward an M1 phenotype.
View Article and Find Full Text PDFNovel Camptothecin Derivative 9c with Enhanced Antitumor Activity via NSA2-EGFR-P53 Signaling Pathway.
Int J Mol Sci
February 2025
Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.
Therapeutic challenges persist in the management of non-small cell lung cancer (NSCLC) in oncology. Camptothecins have demonstrated as crucial agents in tumor therapy; however, their efficacy is significantly hindered by adverse effects and drug resistance. Herein, we present a novel camptothecin derivative named , which exhibits impressive anti-NSCLC potency surpassing the widely recognized camptothecin analog through a novel mechanism.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!